AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by equities research analysts at Shore Capital in a research report issued on Friday.
AZN has been the topic of a number of other reports. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Thursday, July 26th. Deutsche Bank reaffirmed a “buy” rating and set a GBX 6,000 ($78.16) target price on shares of AstraZeneca in a research report on Friday, July 27th. UBS Group set a GBX 4,550 ($59.27) target price on AstraZeneca and gave the stock a “neutral” rating in a research report on Friday, May 18th. Liberum Capital reaffirmed a “hold” rating on shares of AstraZeneca in a research report on Friday, May 18th. Finally, Sanford C. Bernstein raised AstraZeneca to an “outperform” rating and boosted their target price for the stock from GBX 5,673 ($73.90) to GBX 6,026 ($78.49) in a research report on Monday, May 21st. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of GBX 5,689.45 ($74.11).
AZN opened at GBX 5,645 ($73.53) on Friday. AstraZeneca has a one year low of GBX 4,260 ($55.49) and a one year high of GBX 5,520 ($71.90).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.